Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease
provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and …

Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease
that mainly affects the elderly. Typical clinical features include the widespread blisters, often …

Importance Recent studies suggest that dipeptidyl peptidase 4 (DPP-4) inhibitors are
associated with an increased risk of developing bullous pemphigoid (BP). Population-based …

Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP).
The objective of this study was to compare the observed frequency of gliptin intake in a large …

Bullous pemphigoid (BP) is the most common autoimmune bullous skin disease that affects
primarily patients older than 60 years. The majority of BP cases are spontaneous, but BP …

Abstract Dipeptidyl peptidase‐4 (DPP4) is a multifunctional, transmembrane glycoprotein
present on the cell surface of various tissues. It is present in multiple molecular forms …

Abstract Dipeptidyl peptidase-4 inhibitors (DPP-4i or gliptins) increase the risk of developing
bullous pemphigoid (BP). To clarify, whether gliptin-associated BP has special features, we …

Mucous membrane pemphigoids (MMPs) and bullous pemphigoid (BP) are autoimmune
bullous diseases that share physiopathological features: both can result from autoantibodies …

Aims This meta‐analysis aimed to evaluate the risk of developing bullous pemphigoid (BP)
and other skin‐related adverse events (AEs) in patients with type 2 diabetes (T2DM) …

Abstract Dipeptidyl peptidase-4 inhibitors (DPP-4i) have an important place in the
management of type 2 diabetes. The DPP-4 enzyme is ubiquitously distributed throughout …